Search Results
Your search for ,HOW matches 8288 pages
Showing 1451 - 1500World Cancer Day 2023: February 4
World Cancer Day 2023 is now only 1 month away! Led by the Union for International Cancer Control (UICC) and organized annually on February 4, World Cancer Day is a global initiative to improve awareness and knowledge of cancer risks and better prevent, detect, and treat the disease. World Cancer...
Triple Immunotherapy Combination Studied Preclinically for Pancreatic Cancer
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, that successfully reprogrammed the tumor immune microenvironment and significantly improved antitumor responses in...
Uniting on Shared Priorities to Improve Cancer Care: ASCO and ECO Formalize Collaboration With a Memorandum of Understanding
ASCO and the European Cancer Organisation (ECO) are pleased to announce a new collaboration, formalized with a recently signed memorandum of understanding, that will advance their shared aims on cancer control. The two organizations will continue to work together to support the ECO-ASCO Special...
Mirvetuximab Soravtansine for FRɑ-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
On November 14, 2022, the U.S. Food and Drug Administration (FDA) granted mirvetuximab soravtansine-gynx accelerated approval for patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three...
A Lifelong Love of Science Leads to a Leadership Role in Oncology for Laurie Glimcher, MD
For this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Laurie Glimcher, MD, President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute (DFCI). She is also Director of the Dana-Farber/Harvard Cancer Center, Principal...
Chronic Myelomonocytic Leukemia: Treatment and Prognosis, Part 2
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In the concluding half of this two-part installment, which began in our November 25 issue, Drs. Syed Ali Abutalib and Mrinal M. Patnaik continue to explore the current...
Expert Point of View: Joelle Fathi, DNP, RN, ARNP, CTTS, FAAN
An expert on the panel discussion of lung cancer screening from the Quantitative Imaging Workshop XIX, Joelle Fathi, DNP, RN, ARNP, CTTS, FAAN, Chief Healthcare Delivery Officer for the GO2 Foundation for Lung Cancer, called the lung cancer screening study a powerful reminder of the reality on the...
Lung Cancer Screening Perceptions of Patients and Clinicians: The Power of Shared Decision-Making
Despite the benefits of lung cancer screening, including the high cure rate when found by screening compared to being discovered based on symptoms, the uptake of this technique among those who are eligible and where the screening is fully covered by insurance remains dismally low, on the order of...
Managing Severe Diarrhea in Patients With Cancer
Diarrhea in patients with cancer is a well-known phenomenon with clear guidelines for prevention and management. However, it remains a condition with poorly explored consequences and a lack of sufficient and fast-acting treatments. In a webinar presented by members of the Multinational Association...
How ASCO and the Oncology Community Came Together to Discuss Progress in Global Cancer Control and the Challenges Ahead
After a 4-year in-person hiatus because of the COVID-19 global pandemic, the World Cancer Congress, hosted by the Union for International Cancer Control (UICC), held its first hybrid in-person and virtual meeting in October in Geneva. The conference brought together more than 2,000 attendees from...
From the Clinic to the Lab: Overcoming Resistance to Immune Checkpoint Therapy
As a result of breakthroughs in immune checkpoint inhibitors over the past decade, immunotherapy has joined surgery, radiation therapy, and chemotherapy as one of the pillars of cancer treatment. However, nearly half of patients still do not benefit from immune checkpoint blockade. During the 2022...
Research Exposes Inequities in Health-Care Access and Delivery for Blood Disorders
Several studies presented during the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition uncovered significant disparities in medical care and health outcomes among patients of different racial backgrounds, nationalities, and socioeconomic status across a range of blood...
How Telemedicine Can Transform Clinical Research and Practice
The COVID-19 pandemic transformed the world, and nowhere more so than in the health-care arena. Significant changes happened almost overnight in the delivery of medical care to focus on the safety and convenience of patients, staff, and providers. Although pilot efforts to integrate telemedicine...
How the American Cancer Society Aims to Improve Outcomes in Breast and Cervical Cancers and Reduce Health Disparities
Just days before the publication of the 2022 Annual Report to the Nation on the Status of Cancer on October 27, 2022,1 which showed a continued downward trend in cancer deaths, Karen Knudsen, MBA, PhD, Chief Executive Officer of the American Cancer Society (ACS), joined the First Lady Dr. Jill...
Ribociclib Plus Endocrine Therapy vs Combination Chemotherapy for Patients With Breast Cancer: Focus on Those in Visceral Crisis
According to findings from the phase II RIGHT Choice trial, many premenopausal patients with metastatic hormone receptor–positive, HER2-negative breast cancer experiencing visceral crisis are best treated with first-line ribociclib plus endocrine therapy rather than with chemotherapy.1 Ribociclib,...
Quantifying the Population, Clinical, and Scientific Impact of NCTN Research
Clinical trials involving adult patients conducted within the National Cancer Institute’s National Clinical Trials Network (NCTN) over the past 4 decades are estimated to have extended the lives of U.S. patients with cancer by at least 14.2 million patient-years, according to a new study published...
2021 JADPRO Article of the Year Award Spotlights Management of Adverse Events in Immunotherapy
A team of advanced practice providers in the Department of Hematology/Oncology at Fox Chase Cancer Center have received the 2021 Article of the Year Award from the Journal of the Advanced Practitioner in Oncology (JADPRO). This award is given to one article each year that demonstrates an...
Sodium Thiosulfate to Reduce the Risk of Cisplatin-Related Ototoxicity in Pediatric Patients With Localized Solid Tumors
On September 20, 2022, sodium thiosulfate was approved to reduce the risk of ototoxicity associated with cisplatin in pediatric patients (aged ≥ 1 month) with localized, nonmetastatic solid tumors.1 Supporting Efficacy Data Approval was based on findings in the multicenter open-label SIOPEL 6...
Ivosidenib/Azacitidine for Newly Diagnosed IDH1-Mutant Acute Myeloid Leukemia in Patients Aged 75 or Older or With Comorbidities
On May 25, 2022, ivosidenib was approved for use in combination with azacitidine for newly diagnosed acute myeloid leukemia with a susceptible IDH1 mutation, as detected by a U.S. Food and Drug Administration–approved test, in patients aged 75 or older or in those who have comorbidities precluding...
Cedars-Sinai Cancer Leaders Assume New Roles
Lali Medina-Kauwe, PhD, former Co-Leader of the Cancer Biology Program in Cedars-Sinai Cancer, assumed a new role as Associate Director for Basic Research. The Cancer Biology Program will now be led by Dolores Di Vizio, MD, PhD, Professor of Biomedical Sciences, Pathology and Laboratory Medicine in ...
How Do You Move Forward With a Life You Didn’t Choose After a Cancer Diagnosis?
“I was in bed in the surgical wing of Duke University Hospital when the doctor popped his head in and smiled apologetically before flicking on the fluorescent lights. It was 4:00 AM, the end of my second night in the hospital, but nobody sleeps in the conventional sense,” writes Kate Bowler in the...
New Approaches Still Needed to Treat Patients With Cancer Who Have Serious Mental Illness
Although mandates by ASCO and the American Cancer Society to meet the needs of underserved populations have drawn much-needed awareness to the issue, patients with cancer who experience bipolar disorder, schizophrenia, and other debilitating mental illnesses continue to experience significantly...
From Immigrant Roots to a Budding Career in Oncology, Gladys Magaly Rodriguez, MD, Aims to Advance Health Equity in Vulnerable Populations
Gladys Magaly Rodriguez, MD, was born in Piedras Negras, Mexico, a city situated along the banks of the Rio Grande. At age 6, her family immigrated to Eagle Pass, Texas, a border town of some 30,000 people that is predominantly Latinx and Spanish speaking. “Even though I lived and attended school...
Tremelimumab Combined With Durvalumab and Platinum-Based Chemotherapy in Metastatic NSCLC
On November 10, 2022, tremelimu-mab in combination with durvalumab and platinum-based chemotherapy was approved for patients with metastatic non–small cell lung cancer (NSCLC) with no sensitizing EGFR mutation or ALK genomic tumor aberrations.1 Supporting Efficacy Data Approval was supported by...
Alex Herrera, MD, Finds a Path From the Baseball Fields of Miami to a Leadership Role at City of Hope
Lymphoma expert Alex Herrera, MD, was born in Miami; his parents were just 19 years old when he was born. Dr. Herrera’s father was born in Puerto Rico to Cuban and Ecuadorian parents. His mother was born in Cuba and came to the United States via Operation Peter Pan, the clandestine program that...
Indiana University Names Music Therapy Researcher Sheri Robb, PhD, as New Walther Professor of Supportive Oncology
Indiana University (IU) School of Medicine has named Sheri Robb, PhD, a Walther Professor of Supportive Oncology. This is one of five endowed positions to develop a supportive oncology program that encompasses research and patient care. Dr. Robb is a nationally renowned music therapy researcher,...
Brentuximab Vedotin Combined With Chemotherapy in Pediatric Classical Hodgkin Lymphoma
On November 10, 2022, brentuximab vedotin was approved for use in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients aged ≥ 2 years with previously untreated high-risk classical Hodgkin lymphoma.1 Supporting Efficacy Data Approval was...
Study Finds That Patients With Neuroendocrine Cancer and Doctors May Agree on Treatment Goals Only Half of the Time
Researchers revealed that patients with neuroendocrine cancer overwhelmingly prioritized quality of life over living longer, according to a new study published by Li et al in JNCCN–Journal of the National Comprehensive Cancer Network. The researchers surveyed 60 patients with advanced...
Bipartisan Comprehensive Cancer Survivorship Act Introduced
On December 14, U.S. Representative Mark DeSaulnier (D-CA), Representative Debbie Wasserman Schultz (D-FL), Senator Amy Klobuchar (D-MN), Senator Ben Cardin (D-MD), and Representative Brian Fitzpatrick (R-PA) introduced the Comprehensive Cancer Survivorship Act (CCSA)—legislation that will address...
Genome Sequencing of Circulating Tumor Cells in Detection of Myeloma and Precursor Conditions
The novel MinimuMM-seq technique may make it possible to detect tumor cells in individuals at higher risk for multiple myeloma, assess the risk of disease progression in patients with myeloma, and track genetic changes in tumor cells over time from a single blood sample, according to a new study...
Scientists Map Genetic Evolution of CLL to Richter Syndrome
Richter syndrome is an aggressive lymphoma that develops in up to 1% of patients with chronic lymphocytic leukemia (CLL) and it serves as an example of histologic transformation. While recent advances have transformed the treatment landscape of CLL, Richter syndrome remains associated with poor...
Simplified Treatment Regimen Reduces Early Deaths in Patients With APL
The use of a simplified treatment regimen by oncologists—along with management recommendations and 24/7 support provided by a limited and dedicated group of academic disease experts—resulted in a decrease in early deaths from acute promyelocytic leukemia (APL). In the multicenter prospective trial...
Pilot Study Investigates Axicabtagene Ciloleucel in Primary and Secondary CNS Lymphoma
The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel was deemed safe and showed encouraging signs of efficacy in a small pilot trial involving patients with lymphoma of the brain and/or spinal cord, according to findings presented by Caron A. Jacobson, MD, MMSc, and colleagues ...
Report Outlines Advance in Retreatment With CAR T-Cell Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma or CLL
Researchers from the University of Pennsylvania’s Abramson Cancer Center presented preliminary results of an ongoing phase I clinical trial demonstrating successful retreatment with chimeric antigen receptor (CAR) T-cell therapy for patients whose cancers relapsed after previous CAR T-cell therapy. ...
Stephen M. Ansell, MD, PhD, and Patrizia Mondello, MD, PhD: New Findings on How the IRF4 Gene Shapes Tumor Immunity in Follicular Lymphoma
Stephen M. Ansell, MD, PhD, and Patrizia Mondello, MD, PhD, both of the Mayo Clinic, discuss the 20% of patients with follicular lymphoma (FL) who relapse early and experience a poor prognosis. The researchers found that FLs with high levels of IRF4 expression are associated with a suppressive...
Genetic Profiling May Identify Patients With Breast Cancer Who Can Safely Omit Radiation Therapy After Breast-Conserving Surgery
Patients with invasive breast cancer who had low scores on an investigational gene molecular signature had similar rates of local recurrence independent of whether they received adjuvant radiation therapy after breast-conserving surgery, according to findings presented by Karlsson et al at the 2022 ...
Putting the Patient at the Center: The Career of Jeffery Ward, MD, FASCO
Editor’s Note: ASCO was deeply saddened by the news that Dr. Jeff Ward passed away on November 3, 2022. In an interview with Dr. Ward this past summer, published in ASCO Connection (August 30, 2022), ASCO recognized Dr. Ward’s commitment to exceptional patient care and public advocacy. An...
I Have the BRCA2 Gene Mutation: Here’s What I’m Doing to Prevent Cancer
My father was diagnosed with prostate cancer in 1994, when he was just 55 years old. He died 6 years later. The cancer was so aggressive, it took only a few weeks from the time he was diagnosed for the cancer to grow to the size of a softball, and even a radical prostatectomy couldn’t save his...
Heartbreak and a Second Chance at Love and Life
“I knew my husband was dying in June. He’d been living with a terminal diagnosis for 6 years, but suddenly his cancer turned aggressive…. The last time we saw the oncologist, he sent us home with a DNR order and told me to put it on the refrigerator, because that’s where the EMTs look,” writes...
World Travel Helped Brittany L. Bychkovsky, MD, MSc, Shape Her Global Commitment to Breast Cancer Care
Breast cancer specialist Brittany L. Bychkovsky, MD, MSc, grew up primarily in Kansas; however, given that her father was a pilot, her childhood was not wholly centered in the Sunflower State. “When I was 12 years old, my mom, who was a schoolteacher, was diagnosed with stage III breast cancer. Her ...
National Academy of Medicine Elects 100 New Members
The National Academy of Medicine recently announced the election of 90 regular members and 10 international members during its annual meeting. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated...
Cemiplimab/Chemotherapy Combination in Advanced NSCLC With No EGFR, ALK, or ROS1 Aberrations
On November 8, 2022, cemiplimab-rwlc was approved for use in combination with platinum-based chemotherapy for first-line treatment of patients with advanced non–small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations.1 Supporting Efficacy Data Approval was supported by findings in the ...
Teclistamab in the Treatment of Relapsed or Refractory Multiple Myeloma
On October 25, 2022, the bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager teclistamab-cqyv was granted accelerated approval for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome...
The Effect of the Reversal of Roe v Wade on Care of Pregnant Women With Cancer
The repercussions from the decision by the U.S. Supreme Court on June 24, 2022, to overturn Roe v Wade, effectively ending a nearly 50-year federal constitutional right to an abortion and allowing instead states to determine abortion access, are starting to be felt in the cancer care community. The ...
Michael A. Caligiuri, MD, Traveled From Humble Beginnings to a Notable Career as an Oncology Leader
In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Michael A. Caligiuri, MD, a physician-scientist who currently serves as President of the City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief...
Dabrafenib in Combination With Trametinib for Unresectable or Metastatic Solid Tumors With BRAF V600E Mutation
On June 22, 2022, dabrafenib in combination with trametinib was granted accelerated approval for treatment of adult and pediatric patients (aged 6 and older) with unresectable or metastatic solid tumors with BRAF V600E mutation whose disease progressed following prior treatment and who have no...
ASCO Guideline Highlights Newest Breakthroughs in the Treatment of Metastatic Colorectal Cancer
A new ASCO guideline on the management of advanced colorectal cancer summarizes the latest treatments supported by quality data that could expand oncologists’ armamentarium and potentially improve survival outcomes.1 “[Colorectal cancer] remains the second-leading class of cancer deaths among men ...
Durvalumab Plus Chemotherapy in Advanced Biliary Tract Cancer
On September 2, 2022, durvalumab was approved for use in combination with gemcitabine/cisplatin for the treatment of patients with locally advanced or metastatic biliary tract cancer.1 Supporting Efficacy Data Approval was based on findings in the double-blind TOPAZ-1 trial (NCT03875235), in which...
Futibatinib for Cholangiocarcinoma With FGFR2 Gene Fusion or Other Rearrangements
On September 30, 2022, futibatinib was granted accelerated approval for adults with previously treated, unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.1 Supporting Efficacy ...
How Low-Dose Oral Minoxidil Is Providing Hope for Patients With Later-Stage Alopecia
Chemotherapy-induced hair loss affects 65% of patients with cancer,1 and the psychosocial impact on these patients can be profound; it may include anxiety, depression, a negative body image, lowered self-esteem, and a reduced sense of well-being.2 In some instances, the fear of hair loss from...
